Global Skin Cancer Diagnostics & Therapeutics Market Report 2023: Rising Government Initiatives for Early Detection and Skin Cancer Treatment Bolsters Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Skin Cancer Diagnostics & Therapeutics Market by Disease Type (Melanoma, Non-melanoma), Type (Diagnosis, Therapeutics) - Cumulative Impact of High Inflation - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.

The Global Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 6,842.50 million in 2022, USD 7,542.59 million in 2023, and is projected to grow at a CAGR of 10.41% to reach USD 15,111.45 million by 2030.

Market Dynamics

Drivers

• Growing Incidences and Rising Awareness of Skin Cancer Globally
• Rising Government Initiatives for Early Detection and Skin Cancer Treatment
• Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics

Restraints

• High Cost Associated With the Various Skin Cancer Treatment

Opportunities

• Advancements in Skin Cancer Diagnostics & Therapeutics
• Developments of Skin Cancer Care in Emerging Nations

Challenges

• Side Effects of Radiation Therapy for Skin Cancer

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

• Based on Disease Type, the market is studied across Melanoma and Non-melanoma.
• Based on Type, the market is studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy. The Therapeutics is further studied across Chemotherapy, Non-invasive Therapy, and Surgery.
• Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Arizona, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Nevada, Ohio, Oregon, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Skin Cancer Diagnostics & Therapeutics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Skin Cancer Diagnostics & Therapeutics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Skin Cancer Diagnostics & Therapeutics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Skin Cancer Diagnostics & Therapeutics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor's strengths and weaknesses, providing insights to enhance products and services.

The report answers questions such as:

1. What is the market size and forecast of the Global Skin Cancer Diagnostics & Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Skin Cancer Diagnostics & Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Skin Cancer Diagnostics & Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Skin Cancer Diagnostics & Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Skin Cancer Diagnostics & Therapeutics Market?

6. What is the market share of the leading vendors in the Global Skin Cancer Diagnostics & Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Skin Cancer Diagnostics & Therapeutics Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

6.1. Introduction

6.2. Melanoma

6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Type

7.1. Introduction

7.2. Diagnosis

7.3.1. Blood Tests

7.3.2. Dermatoscopy

7.3.3. Imaging Tests

7.3.4. Lymph Node Biopsy

7.3.5. Skin Biopsy

7.3. Therapeutics

7.4.1. Chemotherapy

7.4.2. Non-invasive Therapy

7.4.3. Surgery

8. Americas Skin Cancer Diagnostics & Therapeutics Market

8.1. Introduction

8.2. Argentina

8.3. Brazil

8.4. Canada

8.5. Mexico

8.6. United States

9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

9.1. Introduction

9.2. Australia

9.3. China

9.4. India

9.5. Indonesia

9.6. Japan

9.7. Malaysia

9.8. Philippines

9.9. Singapore

9.10. South Korea

9.11. Taiwan

9.12. Thailand

9.13. Vietnam

10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

10.1. Introduction

10.2. Denmark

10.3. Egypt

10.4. Finland

10.5. France

10.6. Germany

10.7. Israel

10.8. Italy

10.9. Netherlands

10.10. Nigeria

10.11. Norway

10.12. Poland

10.13. Qatar

10.14. Russia

10.15. Saudi Arabia

10.16. South Africa

10.17. Spain

10.18. Sweden

10.19. Switzerland

10.20. Turkey

10.21. United Arab Emirates

10.22. United Kingdom

11. Competitive Landscape

12. Company Usability Profiles

13. Appendix

Companies Mentioned

• AB Science
• Abbott Laboratories
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Castle Biosciences, Inc.
• Daiichi Sankyo Company, Limited
• DermTech
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• NeraCare GmbH
• Novartis AG
• Pfizer Inc.
• Qiagen NV
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/prabfv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900